The DOT Office of Drug and Alcohol Policy and Compliance (ODAPC) has posted four guidance related notices

The Department of Transportation Office of Drug and Alcohol Policy and Compliance (ODAPC) has posted four guidance related notices on the 49 CFR Part 40 Final Rule, which goes into effect on January 1, 2018 Part 40 DOT Employee Notice 2017

DOT Employer Alert: Part 40 DOT Employee Notice 2017

The Department of Transportation Office of Drug and Alcohol Policy and Compliance (ODAPC) has posted four guidance related notices on the 49 CFR Part 40 Final Rule, which goes into effect on January 1, 2018, at https://www.transportation.gov/odapc/frpubs .

The most current one is as follows and can be found at:
https://www.transportation.gov/odapc/Part_40_DOT_Employee_Notice_2017

DOT service agents and employers should consider checking the https://www.transportation.gov/odapc/frpubs  regularly, although First Advantage’s Chief Global Compliance Officer is also closely monitoring 49 CFR Part 40 Final Rule ODAPC updates as well. Please be aware that such guidance notices may become available prior to going out on ODAPC’s List Serve.

To subscribe to List Serve please go to:
https://www.transportation.gov/odapc/ListServe_Notices

It is recommended that the following be considered in a DOT employer’s approach to its DOT employer notification on the new 49 CFR Part 40 Final Rule, effective January 1, 2018, along with any necessary updates to its DOT Operating Administration/Modal/Agency Policy.

Please also see the following guidance regarding possible necessitated policy updates : https://www.transportation.gov/odapc/Part_40_DOT_Policies_Notice_2017

Given the short turn around for the implementation of the Final Rule, DOT employer’s that need to update their policies as per the following guidance, could consider publishing an interim Policy Addendum on the regulatory changes prior to a full update to its DOT policy(s).

https://www.transportation.gov/odapc/Part_40_DOT_Employee_Notice_2017

DOT Drug Testing: Part 40 – Employee Notice

This is a reminder that the U.S. Department of Transportation (DOT) drug testing program will soon require testing for four semi-synthetic opioids (i.e., hydrocodone, oxycodone, hydromorphone, oxymorphone).  The change is effective January 1, 2018.

What does this mean for the employees?

Beginning January 1, 2018, in addition to the existing DOT drug testing panel (that includes marijuana, cocaine, amphetamines, phencyclidine (PCP), and opiates), you will also be tested for four semi-synthetic opioids (i.e., hydrocodone, oxycodone, hydromorphone, oxymorphone).  Some common names for these semi-synthetic opioids include OxyContin®, Percodan®, Percocet®, Vicodin®, Lortab®, Norco®, Dilaudid®, Exalgo®.

If you test positive for any of the semi-synthetic opioid drugs, then as with any other drug test result that is confirmed by the laboratory, the Medical Review Officer (MRO) will conduct an interview with you to determine if there is a legitimate medical explanation for the result.  If you have a valid prescription, you should provide it to the MRO, who will determine if the prescription is valid.  If a legitimate medical explanation is established, the MRO will report the result to your employer as a ‘negative’.  If not, the MRO will report the result to your employer as ‘positive’.

As it has been the requirement in the past, when your employer receives a ‘positive’ drug test result, your employer is to immediately remove you from performing safety-sensitive functions and provide you with a list of qualified Substance Abuse Professionals (SAP) available in your area.  In order to return to performing safety-sensitive functions for any DOT-regulated employer, you must complete the return-to-duty process that will include an evaluation by a SAP, who will require education and/or treatment.  The SAP will determine if you successfully completed the prescribed education and/or treatment.  Before an employer could return you to safety-sensitive work, the employer must get a negative result on a directly observed return-to-duty drug test.  After you return to safety-sensitive work, you must be subject to directly observed follow-up testing for 12-60 months depending on the SAP’s recommendations.

Do I need to tell anyone about my prescribed medications?

Your employer may have a policy that requires you to report your prescribed medications to them.  So check with your employer.  If your job function has DOT-regulated medical standards (truck/bus driver, airline pilot, mariner), the DOT agency regulation may require you to report your prescribed medications to those who approved your medical qualifications.

What should I tell my prescribing physician?

If you are taking any prescription medications, consider this to be a reminder to have a conversation with your prescribing physician to discuss your safety-sensitive work.  Be proactive in ensuring that your prescribing physician knows what type of transportation-related safety-sensitive work you currently perform.  For example, don’t just provide a job title but describe your exact job function(s) or ask your employer for a detailed description of your job function that you can give to your prescribing physician.  This is important information for your prescribing physician to consider when deciding whether and what medication to prescribe for you.  It is important for you to know whether your medications could impact your ability to safely perform your transportation-related work.

Will the MRO report my prescribed medication use/medical information to a third party?

Historically, the DOT’s regulation required the MRO to report your medication use/medical information to a third party (e.g. your employer, health care provider responsible for your medical qualifications, etc.), if the MRO determines in his/her reasonable medical judgement that you may be medically unqualified according to DOT Agency regulations, or if your continued performance is likely to pose a significant safety risk.  The MRO may report this information even if the MRO verifies your drug test result as ‘negative’.

As of January 1, 2018, prior to the MRO reporting your information to a third party you will have up to five days to have your prescribing physician contact the MRO.  You are responsible for facilitating the contact between the MRO and your prescribing physician.  Your prescribing physician should be willing to state to the MRO that you can safely perform your safety-sensitive functions while taking the medication(s), or consider changing your medication to one that does not make you medically unqualified or does not pose a significant safety risk.

NOTE:   This document informally summarizes some of the effects of recent changes to the Procedures for Transportation Workplace Drug and Alcohol Testing Programs that are important for transportation employees, but it should not be relied upon to determine legal compliance with those procedures.

December 11, 2017